Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

University of Western Ontario

$173,437.00

Non-contact 3D photoacoustic/ultrasonic imaging for detecting the early response to neoadjuvant chemotherapy in breast cancer patients

EF 2017-18

Résumé
Women who have been diagnosed with large or aggressive breast cancers are advised to undergo treatment to shrink thetumour prior to surgery. Treatment usually involves cytotoxic intravenous chemotherapy. Not all women respond to the drugsequally. About 75% of women respond well to the drugs, and tumours are reduced in size so that surgery becomes anoption. In the remaining 25% of women, the drugs have little or no effect in which case mastectomy or palliation are the onlyremaining options. Recently, researchers have discovered that increased levels of oxygen-rich blood in and around breasttumours as early as one day after drug treatment are predictive of tumours that shrink. However, the imaging method usedby the researchers took a long time to perform and could not precisely locate the changes inside the breast. In our work, wewill use non-contact 3D photoacoustic/ultrasonic tomography to quickly and accurately image the distribution of oxygen-richblood inside the breast. We predict that non-contact 3D photoacoustic/ultrasonic tomography will provide a detailed view ofthe oxygen-rich blood inside and around tumours after a single dose of chemotherapy to identify women who respond well tothe drugs and those who do not. If the project is successful, then non-contact 3D photoacoustic/ultrasonic tomography couldbe used by doctors to predict chemotherapy sensitivity as soon as one day after treatment starts, not after several cycles ormonths, as is now the case. For women whose non-contact 3D photoacoustic/ultrasonic tomographic results predict thatthey will not respond to the current treatment, second line chemotherapy regimens or alternative treatment options such asradiation could be selected to shrink the tumours rather than allow them to continue to grow.
Programme
Collaborative Health Research Projects
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
493618-2016
Name nom
Carson, Jeffrey
Department département
Medical Biophysics
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2016
Award amount
173437
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Non-contact 3D photoacoustic/ultrasonic imaging for detecting the early response to neoadjuvant chemotherapy in breast cancer patients
Keyword
NSERC
Application summary
Women who have been diagnosed with large or aggressive breast cancers are advised to undergo treatment to shrink thetumour prior to surgery. Treatment usually involves cytotoxic intravenous chemotherapy. Not all women respond to the drugsequally. About 75% of women respond well to the drugs, and tumours are reduced in size so that surgery becomes anoption. In the remaining 25% of women, the drugs have little or no effect in which case mastectomy or palliation are the onlyremaining options. Recently, researchers have discovered that increased levels of oxygen-rich blood in and around breasttumours as early as one day after drug treatment are predictive of tumours that shrink. However, the imaging method usedby the researchers took a long time to perform and could not precisely locate the changes inside the breast. In our work, wewill use non-contact 3D photoacoustic/ultrasonic tomography to quickly and accurately image the distribution of oxygen-richblood inside the breast. We predict that non-contact 3D photoacoustic/ultrasonic tomography will provide a detailed view ofthe oxygen-rich blood inside and around tumours after a single dose of chemotherapy to identify women who respond well tothe drugs and those who do not. If the project is successful, then non-contact 3D photoacoustic/ultrasonic tomography couldbe used by doctors to predict chemotherapy sensitivity as soon as one day after treatment starts, not after several cycles ormonths, as is now the case. For women whose non-contact 3D photoacoustic/ultrasonic tomographic results predict thatthey will not respond to the current treatment, second line chemotherapy regimens or alternative treatment options such asradiation could be selected to shrink the tumours rather than allow them to continue to grow.